Patient characteristics
| . | No cGVHD (n = 13) . | Mild cGVHD (n = 20) . | Moderate cGVHD (n = 16) . | Severe cGVHD (n = 12) . | P . |
|---|---|---|---|---|---|
| Age, y | NS | ||||
| Median | 55 | 62 | 55 | 61 | |
| Range | 36-71 | 32-73 | 26-72 | 38-71 | |
| Sex | NS | ||||
| Male | 9 (69) | 13 (65) | 9 (57) | 6 (50) | |
| Female | 4 (31) | 7 (35) | 7 (43) | 6 (50) | |
| Diseases | NS | ||||
| AML | 4 (31) | 9 (45) | 5 (32) | 4 (34) | |
| ALL | 1 (7) | 2 (10) | 2 (12) | 0 (8) | |
| CML | 1 (7) | 1 (5) | 1 (6) | 1 (8) | |
| CLL | 4 (31) | 2 (10) | 1 (6) | 3 (25) | |
| NHL | 3 (24) | 4 (20) | 6 (38) | 0 (0) | |
| MDS | 0 (0) | 1 (5) | 1 (6) | 3 (25) | |
| MF | 0 (0) | 1 (5) | 0 (0) | 0 (0) | |
| AA | 0 (0) | 0 (0) | 0 (0) | 1 (8) | |
| Conditioning regimen | NS | ||||
| Myeloablative | 2 (15) | 5 (25) | 6 (37) | 3 (25) | |
| Nonmyeloablative | 11 (85) | 15 (75) | 10 (63) | 9 (75) | |
| Donor source | NS | ||||
| MRD | 4 (31) | 7 (35) | 7 (43) | 3 (25) | |
| MUD | 9 (69) | 13 (65) | 9 (57) | 9 (75) | |
| Stem cell source | NS | ||||
| BMT | 1 (7) | 2 (10) | 1 (6) | 0 (0) | |
| PBSCT | 12 (93) | 18 (90) | 15 (94) | 12 (100) | |
| Donor age at sampling, y | NS | ||||
| Median | 42 | 43 | 39 | 40 | |
| Range | 24-57 | 26-67 | 23-60 | 23-57 | |
| Sex matching (recipient/donor) | NS | ||||
| Male/male | 6 (47) | 9 (45) | 5 (31) | 3 (25) | |
| Male/female | 3 (23) | 4 (20) | 4 (25) | 3 (25) | |
| Female/male | 2 (15) | 4 (20) | 5 (31) | 3 (25) | |
| Female/female | 2 (15) | 3 (15) | 2 (13) | 3 (25) | |
| Medication | |||||
| Predonisone | 1 (8) | 13 (65) | 11 (69) | 11 (92) | NS |
| Tacrolimus | 2 (16) | 5 (25) | 4 (25) | 7 (59) | NS |
| Sirolimus | 1 (8) | 4 (20) | 2 (13) | 7 (59) | .02 |
| MMF | 0 (0) | 1 (5) | 4 (25) | 4 (33) | NS |
| ECP | 0 (0) | 3 (15) | 1 (7) | 3 (25) | NS |
| Acute GVHD prophylaxis | |||||
| Tacrolimus/sirolimus | 3 (24) | 6 (30) | 4 (25) | 3 (25) | |
| Tacrolimus/MTX | 1 (8) | 5 (25) | 5 (31) | 1 (8) | |
| Tacrolimus/sirolimus/MTX | (62) | 9 (45) | 6 (38) | 6 (50) | |
| Others | 1 (8) | 0 (0) | 1 (6) | 2 (17) | |
| Acute GVHD grade 2-4 | NS | ||||
| No | 7 (54) | 16 (80) | 9 (56) | 7 (58) | |
| Yes | 6 (46) | 4 (20) | 7 (44) | 5 (42) | |
| cGVHD target organ | |||||
| Skin | 0 (0) | 15 (75) | 10 (63) | 10 (84) | NS |
| Mouth | 0 (0) | 5 (25) | 9 (57) | 6 (50) | NS |
| Eye | 0 (0) | 3 (15) | 6 (37) | 9 (75) | .003 |
| Liver | 0 (0) | 0 (0) | 4 (25) | 3 (25) | .054 |
| Lung | 0 (0) | 0 (0) | 2 (13) | 2 (17) | NS |
| Muscle | 0 (0) | 4 (20) | 3 (19) | 5 (42) | NS |
| Joint and fascia | 0 (0) | 1 (5) | 0 (0) | 2 (17) | NS |
| Median time after transplantation, days | |||||
| Median | 1249 | 1503 | 1207 | 1208 | NS |
| Range | 856-2711 | 757-2739 | 754-2768 | 772-3492 |
| . | No cGVHD (n = 13) . | Mild cGVHD (n = 20) . | Moderate cGVHD (n = 16) . | Severe cGVHD (n = 12) . | P . |
|---|---|---|---|---|---|
| Age, y | NS | ||||
| Median | 55 | 62 | 55 | 61 | |
| Range | 36-71 | 32-73 | 26-72 | 38-71 | |
| Sex | NS | ||||
| Male | 9 (69) | 13 (65) | 9 (57) | 6 (50) | |
| Female | 4 (31) | 7 (35) | 7 (43) | 6 (50) | |
| Diseases | NS | ||||
| AML | 4 (31) | 9 (45) | 5 (32) | 4 (34) | |
| ALL | 1 (7) | 2 (10) | 2 (12) | 0 (8) | |
| CML | 1 (7) | 1 (5) | 1 (6) | 1 (8) | |
| CLL | 4 (31) | 2 (10) | 1 (6) | 3 (25) | |
| NHL | 3 (24) | 4 (20) | 6 (38) | 0 (0) | |
| MDS | 0 (0) | 1 (5) | 1 (6) | 3 (25) | |
| MF | 0 (0) | 1 (5) | 0 (0) | 0 (0) | |
| AA | 0 (0) | 0 (0) | 0 (0) | 1 (8) | |
| Conditioning regimen | NS | ||||
| Myeloablative | 2 (15) | 5 (25) | 6 (37) | 3 (25) | |
| Nonmyeloablative | 11 (85) | 15 (75) | 10 (63) | 9 (75) | |
| Donor source | NS | ||||
| MRD | 4 (31) | 7 (35) | 7 (43) | 3 (25) | |
| MUD | 9 (69) | 13 (65) | 9 (57) | 9 (75) | |
| Stem cell source | NS | ||||
| BMT | 1 (7) | 2 (10) | 1 (6) | 0 (0) | |
| PBSCT | 12 (93) | 18 (90) | 15 (94) | 12 (100) | |
| Donor age at sampling, y | NS | ||||
| Median | 42 | 43 | 39 | 40 | |
| Range | 24-57 | 26-67 | 23-60 | 23-57 | |
| Sex matching (recipient/donor) | NS | ||||
| Male/male | 6 (47) | 9 (45) | 5 (31) | 3 (25) | |
| Male/female | 3 (23) | 4 (20) | 4 (25) | 3 (25) | |
| Female/male | 2 (15) | 4 (20) | 5 (31) | 3 (25) | |
| Female/female | 2 (15) | 3 (15) | 2 (13) | 3 (25) | |
| Medication | |||||
| Predonisone | 1 (8) | 13 (65) | 11 (69) | 11 (92) | NS |
| Tacrolimus | 2 (16) | 5 (25) | 4 (25) | 7 (59) | NS |
| Sirolimus | 1 (8) | 4 (20) | 2 (13) | 7 (59) | .02 |
| MMF | 0 (0) | 1 (5) | 4 (25) | 4 (33) | NS |
| ECP | 0 (0) | 3 (15) | 1 (7) | 3 (25) | NS |
| Acute GVHD prophylaxis | |||||
| Tacrolimus/sirolimus | 3 (24) | 6 (30) | 4 (25) | 3 (25) | |
| Tacrolimus/MTX | 1 (8) | 5 (25) | 5 (31) | 1 (8) | |
| Tacrolimus/sirolimus/MTX | (62) | 9 (45) | 6 (38) | 6 (50) | |
| Others | 1 (8) | 0 (0) | 1 (6) | 2 (17) | |
| Acute GVHD grade 2-4 | NS | ||||
| No | 7 (54) | 16 (80) | 9 (56) | 7 (58) | |
| Yes | 6 (46) | 4 (20) | 7 (44) | 5 (42) | |
| cGVHD target organ | |||||
| Skin | 0 (0) | 15 (75) | 10 (63) | 10 (84) | NS |
| Mouth | 0 (0) | 5 (25) | 9 (57) | 6 (50) | NS |
| Eye | 0 (0) | 3 (15) | 6 (37) | 9 (75) | .003 |
| Liver | 0 (0) | 0 (0) | 4 (25) | 3 (25) | .054 |
| Lung | 0 (0) | 0 (0) | 2 (13) | 2 (17) | NS |
| Muscle | 0 (0) | 4 (20) | 3 (19) | 5 (42) | NS |
| Joint and fascia | 0 (0) | 1 (5) | 0 (0) | 2 (17) | NS |
| Median time after transplantation, days | |||||
| Median | 1249 | 1503 | 1207 | 1208 | NS |
| Range | 856-2711 | 757-2739 | 754-2768 | 772-3492 |
All P values indicate comparisons among 4 cGVHD groups, except for medication and cGVHD target organ, among mild, moderate, and severe cGVHD groups. Values in parentheses are percentages.
NS indicates not significant; AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myeloid leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndrome; MF, myclofibrosis; AA, aplastic anemia; MRD, matched related donor; MUD, matched unrelated donor; BMT, bone marrow transplantation; PBSCT, peripheral blood stem cell transplantation; MMF, mycophenolate mofetil; ECP, extracorporeal photopheresis; and MTX, methotrexate.